featured
Identifying the Optimal Therapeutics for Patients With HR+/HER2+ Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis
ESMO Open 2023 Apr 19;8(3)101216, Y Wang, H Xu, Y Han, Y Wu, Q Sa, J WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.